GBT announces updated efficacy data from all patients Enrolled in phase 3 HOPE study
Global Blood Therapeutics announced new results from its Phase 3 HOPE Study of voxelotor in patients ages 12 and older with sickle cell disease. The findings from 274 adolescents and adults treated with voxelotor showed the HOPE Study met its primary endpoint of an improvement in hemoglobin. June 14, 2019